WRBY Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -2.12% compared to Warby Parker's net margin of --. Warby Parker's return on equity of -10.25% beat Perspective Therapeutics's return on equity of --.

Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.18%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 390.88%. Given that Perspective Therapeutics has higher upside potential than Warby Parker, analysts believe Perspective Therapeutics is more attractive than Warby Parker.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $192.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Warby Parker's net income of -$4.1M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Warby Parker's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.03x versus 17.77x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Daxor has a net margin of -2.12% compared to Warby Parker's net margin of --. Warby Parker's return on equity of -10.25% beat Daxor's return on equity of 5.22%.

Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.18%. On the other hand Daxor has an analysts' consensus of -- which suggests that it could grow by 194.03%. Given that Daxor has higher upside potential than Warby Parker, analysts believe Daxor is more attractive than Warby Parker.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daxor has a beta of -0.508, suggesting its less volatile than the S&P 500 by 150.824%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Daxor pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $192.4M, which are larger than Daxor quarterly revenues of --. Warby Parker's net income of -$4.1M is higher than Daxor's net income of --. Notably, Warby Parker's price-to-earnings ratio is -- while Daxor's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.03x versus 14.70x for Daxor. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics has a net margin of -2.12% compared to Warby Parker's net margin of -31.24%. Warby Parker's return on equity of -10.25% beat Precision Optics's return on equity of -34.86%.

Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.18%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Warby Parker has higher upside potential than Precision Optics, analysts believe Warby Parker is more attractive than Precision Optics.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precision Optics has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.901%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $192.4M, which are larger than Precision Optics quarterly revenues of $4.2M. Warby Parker's net income of -$4.1M is lower than Precision Optics's net income of -$1.3M. Notably, Warby Parker's price-to-earnings ratio is -- while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.03x versus 1.66x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech has a net margin of -2.12% compared to Warby Parker's net margin of -13.19%. Warby Parker's return on equity of -10.25% beat Sanara MedTech's return on equity of -19.67%.

Warby Parker has a consensus price target of $22.23, signalling downside risk potential of -11.18%. On the other hand Sanara MedTech has an analysts' consensus of $44.00 which suggests that it could grow by 37.43%. Given that Sanara MedTech has higher upside potential than Warby Parker, analysts believe Sanara MedTech is more attractive than Warby Parker.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanara MedTech has a beta of 1.574, suggesting its more volatile than the S&P 500 by 57.373%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Sanara MedTech pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $192.4M, which are larger than Sanara MedTech quarterly revenues of $21.7M. Warby Parker's net income of -$4.1M is lower than Sanara MedTech's net income of -$2.9M. Notably, Warby Parker's price-to-earnings ratio is -- while Sanara MedTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 4.03x versus 3.70x for Sanara MedTech. Usually stocks with elevated PS ratios are considered overvalued.